Dear Editor, We thank Chen et al. for their thoughtful comments on our study evaluating camrelizumab plus apatinib with or without transarterial chemoembolisation (TACE) as first-line treatment for advanced hepatocellular carcinoma (HCC) [1, 2]. First, we agree that TACE-related heterogeneity is an important consideration.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile